CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment, 32392 [2013-12857]
Download as PDF
<![CDATA[
32392
Federal Register / Vol. 78, No. 104 / Thursday, May 30, 2013 / Notices
attending, and if participating via
webcast or in-person.
Webcast Public Participation: After
pre-registration, individuals
participating by webcast will receive
webcast access information via email.
In-Person Public Participation and
Building Access: For in-person
participants, the meetings are within the
National Institutes of Health (NIH)
Clinical Center (Building 10) as noted
above in the Addresses section. Details
regarding registration capacity and
directions will be posted on
www.DietaryGuidelines.gov. For inperson participants, check-in at the
registration desk onsite at the meeting is
required and will begin at 7:30 a.m.
each day.
Public Comments and Meeting
Documents: Written comments from the
public will be accepted throughout the
Committee’s deliberative process;
opportunities to present oral comments
to the Committee will be provided at a
future meeting. Written public
comments can be submitted and/or
viewed at www.DietaryGuidelines.gov
using the ‘‘Submit Comments’’ and
‘‘Read Comments’’ links, respectively.
Written comments received by June 5,
2013 will ensure transmission to the
Committee prior to this meeting.
Documents pertaining to Committee
deliberations, including meeting
agendas, summaries, and transcripts
will be available on
www.DietaryGuidelines.gov under
‘‘Meetings’’ and meeting materials will
be available for public viewing at the
meeting. Meeting information,
thereafter, will continue to be accessible
online, at the NIH Library, and upon
request at the Office of Disease
Prevention and Health Promotion,
OASH/HHS; 1101 Wootton Parkway,
Suite LL100 Tower Building; Rockville,
MD 20852: Telephone (240) 453–8280;
Fax: (240) 453–8281.
Dated: May 24, 2013.
Richard Olson,
Designated Federal Officer, Director, Division
of Prevention Science, Office of Disease
Prevention and Health Promotion, Office of
the Assistant Secretary for Health, U.S.
Department of Health and Human Services.
TKELLEY on DSK3SPTVN1PROD with NOTICES
[FR Doc. 2013–12859 Filed 5–24–13; 4:15 pm]
BILLING CODE 4150–32–P
VerDate Mar<15>2010
16:25 May 29, 2013
Jkt 229001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Health Resources and Services
Administration
CDC/HRSA Advisory Committee on
HIV, Viral Hepatitis and STD Prevention
and Treatment
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC) and the
Health Resources and Services
Administration (HRSA) announce the
following meeting of the
aforementioned committee:
Times and Dates: 8:00 a.m.–5:30 p.m., June
18, 2013; 8:00 a.m.–2:30 p.m., June 19, 2013.
Place: CDC Corporate Square, Building 8,
Conference Room 1–ABC, 8 Corporate
Boulevard, Atlanta, Georgia 30329,
Telephone: (404) 639–8317.
Status: Open to the public, limited only by
the space available. The meeting room will
accommodate approximately 100 people.
This meeting is also accessible by
teleconference. Toll-free +1 (866) 718–4584,
Participant code: 8484551.
Status: Open to the public, limited only by
the space available. The meeting room will
accommodate approximately 100 people.
Purpose: This Committee is charged with
advising the Director, CDC and the
Administrator, HRSA, regarding activities
related to prevention and control of HIV/
AIDS, Viral Hepatitis and other STDs, the
support of health care services to persons
living with HIV/AIDS, and education of
health professionals and the public about
HIV/AIDS, Viral Hepatitis and other STDs.
Matters To Be Discussed: Agenda items
include: (1) STD clinical preventive services
in primary care setting and integrating STD
screening and treatment services in HIV care
settings); (2) The test and cure era for
hepatitis C: The public health response to
rising hepatitis C mortality; The impact of
new therapies on health outcomes; and
Building care capacity to increase access to
hepatitis C virus (HCV) therapy; (3) HIV
Medical Monitoring Project: follow up on
Institute of Medicine (IOM) report and other
Affordable Care Act (ACA) issues; (4)
Recommendations for new HIV diagnostic
laboratory testing algorithms; and (5) CHAC
Workgroups Update.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Margie Scott-Cseh, Centers for Disease
Control and Prevention, National Center for
HIV/AIDS, Viral Hepatitis, STD, and TB
Prevention, 1600 Clifton Road NE., Mailstop
E–07, Atlanta, Georgia 30333, Telephone
(404) 639–8317.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register Notices
pertaining to announcements of meetings and
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2013–12857 Filed 5–29–13; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0577]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Requirements for
Submission of Labeling for Human
Prescription Drugs and Biologics in
Electronic Format
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the information collection contained in
the requirements for the submission of
labeling for human prescription drugs
and biologics in electronic format.
DATES: Submit either electronic or
written comments on the collection of
information by July 29, 2013.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT: Ila
S. Mizrachi, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., P150–
400B, Rockville, MD 20850, 301–796–
7726, Ila.mizrachi@fda.hhs.gov.
SUMMARY:
E:\FR\FM\30MYN1.SGM
30MYN1
]]>Agencies
[Federal Register Volume 78, Number 104 (Thursday, May 30, 2013)]
[Notices]
[Page 32392]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-12857]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Health Resources and Services Administration
CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD
Prevention and Treatment
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) and the Health Resources and Services Administration
(HRSA) announce the following meeting of the aforementioned committee:
Times and Dates: 8:00 a.m.-5:30 p.m., June 18, 2013; 8:00 a.m.-
2:30 p.m., June 19, 2013.
Place: CDC Corporate Square, Building 8, Conference Room 1-ABC,
8 Corporate Boulevard, Atlanta, Georgia 30329, Telephone: (404) 639-
8317.
Status: Open to the public, limited only by the space available.
The meeting room will accommodate approximately 100 people. This
meeting is also accessible by teleconference. Toll-free +1 (866)
718-4584, Participant code: 8484551.
Status: Open to the public, limited only by the space available.
The meeting room will accommodate approximately 100 people.
Purpose: This Committee is charged with advising the Director,
CDC and the Administrator, HRSA, regarding activities related to
prevention and control of HIV/AIDS, Viral Hepatitis and other STDs,
the support of health care services to persons living with HIV/AIDS,
and education of health professionals and the public about HIV/AIDS,
Viral Hepatitis and other STDs.
Matters To Be Discussed: Agenda items include: (1) STD clinical
preventive services in primary care setting and integrating STD
screening and treatment services in HIV care settings); (2) The test
and cure era for hepatitis C: The public health response to rising
hepatitis C mortality; The impact of new therapies on health
outcomes; and Building care capacity to increase access to hepatitis
C virus (HCV) therapy; (3) HIV Medical Monitoring Project: follow up
on Institute of Medicine (IOM) report and other Affordable Care Act
(ACA) issues; (4) Recommendations for new HIV diagnostic laboratory
testing algorithms; and (5) CHAC Workgroups Update.
Agenda items are subject to change as priorities dictate.
Contact Person for More Information: Margie Scott-Cseh, Centers
for Disease Control and Prevention, National Center for HIV/AIDS,
Viral Hepatitis, STD, and TB Prevention, 1600 Clifton Road NE.,
Mailstop E-07, Atlanta, Georgia 30333, Telephone (404) 639-8317.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register Notices pertaining
to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention
and the Agency for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2013-12857 Filed 5-29-13; 8:45 am]
BILLING CODE 4163-18-P
